Chengdu Easton Biopharmaceuticals Co (SHSE:688513) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Chengdu Easton Biopharmaceuticals Co EBITDA Margin % Related Terms
Chengdu Easton Biopharmaceuticals Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co EBITDA Margin % Chart
SHSE:688513 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a EBITDA Margin % of 14.71% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is 42% below median its historical median of 25.19. Over the past decade, Chengdu Easton Biopharmaceuticals Co's EBITDA Margin % has ranged from 14.65 to 29.65. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #154 out of 936 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Chengdu Easton Biopharmaceuticals Co's EBITDA Margin % too high?
Chengdu Easton Biopharmaceuticals Co's current EBITDA Margin % of 14.71% is 42% below median its 10-year median of 25.19. Over the past 10 years, this metric has ranged from a low of 14.65 to a high of 29.65. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #154 out of 936 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #154 out of 936 companies for EBITDA Margin %. This places Chengdu Easton Biopharmaceuticals Co in the top 17% of its industry — outperforming the majority of peers. Historically, Chengdu Easton Biopharmaceuticals Co's own EBITDA Margin % has ranged from 14.65 to 29.65 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current EBITDA Margin % is 14.71%, which is 42% below median its own 10-year median of 25.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥47.90, compared to a current price of ¥55.10 — trading 15% above its estimated fair value. The current EBITDA Margin % is 14.71%, which is 42% below median its 10-year median of 25.19. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current EBITDA Margin % is 14.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥55.10 is trading 15% above its estimated GF Value™ of ¥47.90.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SHSE:688513:
EBITDA Margin %: 14.71% (42% below median its 10-year median of 25.19)
GF Value™: ¥47.90 vs. price of ¥55.10 (15% above fair value)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Business Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
95GF Score
Get the complete analysis for SHSE:688513
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
